Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Emerg Infect Dis ; 26(8): 1826-1830, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32338590

RESUMEN

In May 2019, we investigated monkeypox in a traveler from Nigeria to Singapore. The public health response included rapid identification of contacts, use of quarantine, and postexposure smallpox vaccination. No secondary cases were identified. Countries should develop surveillance systems to detect emerging infectious diseases globally.


Asunto(s)
Enfermedades Transmisibles Emergentes , Mpox , Enfermedades Transmisibles Emergentes/epidemiología , Humanos , Mpox/diagnóstico , Mpox/epidemiología , Monkeypox virus/genética , Nigeria , Singapur/epidemiología
2.
Vaccine ; 37(29): 3925-3931, 2019 06 27.
Artículo en Inglés | MEDLINE | ID: mdl-31160102

RESUMEN

Influenza outbreaks occur periodically in Long Term Care Facilities (LTCFs) and vaccination is critical in preventing influenza infections. We evaluated the influenza vaccine effectiveness (VE) during respiratory outbreaks in LTCFs reported to the Ministry of Health, Singapore in 2017. A test-negative design was used to estimate the ratio of the odds of testing positive for influenza among vaccinated individuals to the odds among unvaccinated individuals. The VE was calculated as (1-odds ratio) × 100%. For adjusted VE, the estimates were derived using logistic regression adjusted for age group, gender, month of illness, and number of days from date of illness onset till to swab collection date. Estimates by influenza subtypes and post-vaccination time periods (15-180 days & 181-365 days) were also calculated using stratified data. 264 individuals, with 118 laboratory-confirmed influenza cases [32 A(H1N1)pdm09, 75 A(H3N2), 11 A(untypable)], were included in the analysis. No one was identified to be infected with influenza B. The overall adjusted VE estimate was 40.5% (95% CI: -12.2-68.5%), while the subtype-specific adjusted VE estimates were -43.4% (95% CI: -312.4-50.2%) against A(H1N1)pdm09 and 57.1% (95% CI: 5.7-80.5%) against A(H3N2). At 15-180 days post-vaccination period, the adjusted VEs were 59.3% (95% CI: 18.0-79.8%) against all influenza, 35.4% (95% CI: -123.5-81.3%) against A(H1N1)pdm09 and 67.9% (95% CI: 22.5-86.7%) against A(H3N2). Estimates were not significant at 181-365 days post-vaccination. The influenza vaccine showed varying effectiveness among individuals in Singapore's LTCFs in 2017, with a higher effectiveness among those who were more recently vaccinated. It remains an important tool in preventing influenza infections, especially for those who are at high risk of influenza-related complications.


Asunto(s)
Brotes de Enfermedades/estadística & datos numéricos , Vacunas contra la Influenza/inmunología , Gripe Humana/prevención & control , Cuidados a Largo Plazo/estadística & datos numéricos , Vacunación/estadística & datos numéricos , Potencia de la Vacuna , Adulto , Anciano , Anciano de 80 o más Años , Brotes de Enfermedades/prevención & control , Monitoreo Epidemiológico , Femenino , Humanos , Subtipo H1N1 del Virus de la Influenza A , Subtipo H3N2 del Virus de la Influenza A , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/epidemiología , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Proyectos de Investigación , Estudios Retrospectivos , Estaciones del Año , Singapur/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA